EUDA Health Holdings Ltd current report, 24 November 2021

Business Context and Reporting Period

8i Acquisition 2 Corp., a British Virgin Islands special purpose acquisition company, filed this Form 8-K under Item 8.01 and Item 9.01. The reported events occurred on November 24, 2021; the filing was signed December 1, 2021. The company had no operating business or revenue information reported in this filing.

Key Financial and Capitalization Metrics

  • Public offering: 8,625,000 units at $10.00 per unit, consisting of the initial 7,500,000 units and 1,125,000 units issued upon full exercise of the underwriters’ over-allotment option.
  • Gross IPO proceeds: $86.25 million.
  • Private placement: 292,250 private units sold to the sponsor at $10.00 per unit, generating $2.9225 million of gross proceeds.
  • Trust account: $86.25 million of net IPO and private-placement proceeds was deposited into a trust account for the benefit of public shareholders as of November 24, 2021.
  • Each public unit included one ordinary share, one warrant to purchase one-half of an ordinary share, and one right to receive one-tenth of an ordinary share upon completion of an initial business combination.
  • The filing does not provide revenue, profit, cash flow, operating margins, debt, or detailed liquidity figures beyond the trust-account deposit.

Material Changes Versus the Prior Comparable Period

No comparable-period operating results are presented. The material event was the consummation of the company’s initial public offering, the full exercise of the over-allotment option, and the concurrent sponsor private placement.

Guidance, Outlook, Risks, and Unusual Items

  • The filing does not provide financial guidance, an acquisition target, or management projections.
  • Proceeds are held in trust pending an initial business combination and are subject to the terms applicable to the company’s public shareholders.
  • The securities include warrants and rights that may result in future share issuance and dilution upon exercise or conversion.
  • The principal unusual item is the SPAC financing structure, including the trust account and sponsor private placement.

Important Facts for Investors to Verify

  • Confirm the audited November 24, 2021 balance sheet included as Exhibit 99.1, including transaction costs, cash outside the trust, and any liabilities.
  • Verify the terms, exercise prices, expiration provisions, and potential dilution associated with the warrants and rights.
  • Review the company’s deadline and conditions for completing an initial business combination, along with redemption rights and liquidation provisions.
  • Confirm whether the reported $86.25 million trust-account amount represents gross or net proceeds after all applicable offering expenses and underwriting discounts.